Immunohistochemical expression of interleukin-2 receptor and interleukin-6 in patients with prostate cancer and benign prostatic hyperplasia: Association with asymptomatic inflammatory prostatitis NIH category IV

References

• Siegl R, Naishadaham D, Jemal A. Cancer statistics 2013. CA Cancer J Clin 2013;63:11–30.
   Google Scholar
• Ferlay J, Steliarova-Foucher E, Loret-Tieulent J, Rosso S, Coebergeh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374–403.
   PubMed Web of Science ®Google Scholar
• Culig Z, Puhr M. Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol 2012;360:52–8.
   PubMed Web of Science ®Google Scholar
• Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab to enhance immune response to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 2009;1174:99–106.
   PubMed Web of Science ®Google Scholar
• Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with greater overall survival benefit from sipuleucl-T in immunotherapy for prostate adenocarcinoma treatment (IMPACT) trial. Urology 2013;81:1297–302.
   PubMed Web of Science ®Google Scholar
• Fox HS, Bond BL, Parslow TG. Estrogen regulates the IFN-γ promoter. J Immunol 1991;146:4362–7
   PubMed Web of Science ®Google Scholar
• Kramer G, Steiner GE, Handisurya A, Stix U, Haitel A, Knerer B, et al. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostatic tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 2002;52:43–58.
   PubMed Web of Science ®Google Scholar
• Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, et al. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 1998;51:161–7.
   PubMed Web of Science ®Google Scholar
• Handisurya A, Steiner GE, Stix U, Ecker RC, Pfaffeneder-Mantai S, Langer D, et al. Differential expression of interleukin-15, a pro-inflammatory cytokine and T-cell growth factor, and its receptor in human prostate. Prostate 2001;49:251–62.
   PubMedGoogle Scholar
• Steiner GE, Newman ME, Paikl D, Stix U, Memaran-Dagda N, Lee C, et al. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 2003;56:171–82.
   PubMed Web of Science ®Google Scholar
• Poutahidis T, Rao VP, Olipitz W, Taylor CL, Jackson EA, Levkovich T, et al. CD4+ lymphocytes modulate prostate cancer progression in mice. Int J Cancer 2009;125:868–78.
   Google Scholar
• Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013;38:13–25.
   PubMed Web of Science ®Google Scholar
• Kuhn DJ, Dou QP. The role of interleukin-2 receptor alpha in cancer. Front Biosci 2005;10:1462–74.
   PubMed Web of Science ®Google Scholar
• Vergati M, Cereda V, Madan RA, Gulley JL, Huen NY, Rogers CJ, et al. Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. Cancer Immunol Immunother 2011;60:197–206.
   PubMed Web of Science ®Google Scholar
• Akins EJ, Moore ML, Tang S, Willingham MC, Tooze JA, Dubey P. In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific PTEN knockout mice. Cancer Res 2010;70:3473–82.
   Google Scholar
• Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, Wheeler TM, et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 2007;13:6947–58.
   PubMed Web of Science ®Google Scholar
• Ebelt K, Barbaryka G, Frankenberger B, Stief CG, Eisenmenger W, Kirchner T, et al. Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. Eur J Cancer 2009;45:1664–72.
   Google Scholar
• Miller AM, Lundberg K, Ozenci V, Banham AH, Hellström M, Egevad L, et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006;177:7398–405.
   PubMed Web of Science ®Google Scholar
• Culig Z, Bartsch G, Hobisch A. Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol Cell Endocrinol 2002;197:231–8.
   PubMedGoogle Scholar
• Santer FR, Malinowska K, Culig Z, Cavarretta IT. Interleukin-6 trans-signaling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr Relat Cancer 2010;17:241–53.
   PubMed Web of Science ®Google Scholar
• Tsui KH, Lin YF, Chen YH, Chang PL, Juang HH. Mechanisms by which interleukin-6 regulates prostate-specific antigen expression in prostate LNCaP carcinoma cells. J Androl 2011;32:383–93.
   Google Scholar
• Krieger JN, Nyberg L. Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999;281:236–7.
   Google Scholar
• Sciarra A, Di Silverio F, Salciccia S, Gomez AAG, Gentilucci A, Gentile V. Inflammation and chronic prostatic diseases: evidence for a link? Eur Urol 2007;52:964–72.
   PubMed Web of Science ®Google Scholar
• De Nunzio C, Kramer G, Marberger M, Nelson W, Schröder F, Sciarra A, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 2011;60:106–17.
   PubMed Web of Science ®Google Scholar
• Engelhardt PF, Brustmann H, Seklehner S, Riedl CR. Chronic asymptomatic inflammation of the prostate type IV and carcinoma of the prostate: is there a correlation? Scand J Urol 2013;47:230–5.
   Web of Science ®Google Scholar
• Konig JE, Senge T, Alhoff EP, Konig W. Analysis of the inflammatory network in benign prostate hyperplasia and prostatic cancer. Prostate 2004;58:121–31.
   PubMed Web of Science ®Google Scholar
• Shah R, Mucci NR, Amin A, Macoska JA, Rubin MA. Prostatic hyperplasia and the prostate gland: neoplastic precursor or innocent bystander? Am J Pathol 2001;158:1767–72.
   PubMed Web of Science ®Google Scholar
• De Marzo AM, March VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999;155:1985–90.
   PubMed Web of Science ®Google Scholar
• Irani J, Levillian P, Gouion JM, Bon D, Dore B, Aubert J. Inflammation in benign prostatic hyperplasia: correlation with prostatic specific antigen value. J Urol 1997;157:1301–3.
   PubMed Web of Science ®Google Scholar
• Reiner A, Spona J, Reiner G, Schemper M, Kolb R, Kwasny W, et al. Estrogen receptor analysis on biopsies and fine-needle aspirates from human breast carcinoma. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Am J Pathol 1986;125:443–9.
   PubMed Web of Science ®Google Scholar
• Reiner A, Neumeister B, Spona J, Reiner G, Schemper M, Jakesz R. Immunohistochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res 1990;50:7057–61.
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Matsuda Y, Takai M, Tasaki T, Tai K, Hososn N, et al. Early relapse is associated with high serum soluble interleukin-2 receptor after the six cycle of R-CHOP chemotherapy in patients with advanced diffuse large B-cell lymphoma. Anticancer Res 2012;32:5051–7.
   PubMed Web of Science ®Google Scholar
• Yokokawa J, Cereda V, Remondo C, Gulley JL, Arlen PM, Schlom J, et al. Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 2008;14:1032–40.
   PubMed Web of Science ®Google Scholar
• Huen NY, Pang AL, Tucker JA, Lee TL, Vergati M, Jochems C, et al. Up-Regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer. Int J Cancer 2013;133:373–82.
   Google Scholar
• Zhao E, Wang L, Dai J, Kryczek I, Wie S, Vatan L, et al. Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer. Oncoimmunology 2012;1:152–61.
   PubMed Web of Science ®Google Scholar
• Cardillo MR, Ippoliti F. IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis. Anticancer Res 2006;26:3409–16.
   PubMed Web of Science ®Google Scholar
• Sugimoto Y, Hirota M, Yoshikawa K, Sumitomo M, Nakamura K, Ueda R, et al. The therapeutic potential of a novel PSMA antibody and its IL-2 conjugate in prostate cancer. Anticancer Res 2014;34:89–97.
   PubMedGoogle Scholar
• Merz C, Nowak M, Vogel W, Svensson MA, Carlsson J, Andren O, et al. The stimulating effect of interleukin-6 in TMPRSS2-ERG positive prostate cancer. Presented at 103rd annual meeting of USCAP in San Diego, March 2014. Mod Pathol 2014;27:248A.
   Google Scholar
• Puskas J, Skrombolas D, Sedlacek A, Lord E, Sullivan M, Frelinger J. Development of an attenuated interleukin-2 fusion protein that can be activated by tumor-expressed proteases. Immunology 2011;133:206–20.
   PubMed Web of Science ®Google Scholar
• Sakai I, Miyake H, Terakawa T, Fujisawa M. Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model. Cancer Sci 2011;102:769–75.
   Google Scholar